Preventing arteriovenous shunt failure in hemodialysis patients: a population-based cohort study. 2019

P Y Fan, and C C Lee, and S H Liu, and I-J Li, and C H Weng, and K H Tu, and M Y Hsieh, and C F Kuo, and T-Y Chang, and Y C Tian, and C W Yang, and H H Wu
Department of Nephrology, Kidney Research Center, Chang Gung Memorial Hospital, Taoyuan, , Taiwan.

Essentials Uncertainty remains about antiplatelets for vascular access patency in hemodialysis patients. 95 971 people under hemodialysis were followed in a claims database in Taiwan. Aspirin reduced vascular access failure rate and did not increase major bleeding rate. Clopidogrel, Aggrenox, and warfarin might increase major bleeding rate. SUMMARY: Background Dialysis adequacy is a major determinant of survival for patients with end-stage renal disease. Good vascular access is essential to achieve adequate dialysis. Objectives This study evaluated the impacts of different drugs on the vascular access failure rate of an arteriovenous fistula or an arteriovenous graft and the rate of major bleeding in hemodialysis patients. Patients and methods We studied patients with end-stage renal disease registered in the Taiwan National Health Insurance program from 1 January 1997 to 31 December 2012. A total of 95 971 patients were enrolled in our study. Vascular access dysfunction was defined as the need for thrombectomy or percutaneous angioplasty. Major bleeding was defined as emergency department visits or hospitalization with a primary diagnosis of gastrointestinal bleeding or intracerebral hemorrhage. The adjusted odds ratios between person-quarters with or without antiplatelet or oral anticoagulant use were calculated using a generalized estimating equation. Results The odds ratio of vascular access failure was 0.21 (0.11-0.39) for aspirin, 0.76 (0.74-0.79) for clopidogrel, 0.67 (0.59-0.77) for dipyridamole, 0.67 (0.53-0.86) for Aggrenox and 0.96 (0.90-1.03) for warfarin. The highest odds ratio for intracerebral hemorrhage was 5.33 (1.25-22.72) in younger patients using Aggrenox. The highest odds ratio for gastrointestinal bleeding was 1.34 (1.10-1.64) for clopidogrel. Conclusion Antiplatelet agents, but not warfarin, might reduce the vascular access thrombosis rate. The gastrointestinal bleeding rate was increased in the group using clopidogrel. Aggrenox should be used with caution in young individuals because it might increase the rate of intracerebral hemorrhage.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010975 Platelet Aggregation Inhibitors Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. Antiaggregants, Platelet,Antiplatelet Agent,Antiplatelet Agents,Antiplatelet Drug,Blood Platelet Aggregation Inhibitor,Blood Platelet Antagonist,Blood Platelet Antiaggregant,PAR-1 Antagonists,Platelet Aggregation Inhibitor,Platelet Antagonist,Platelet Antagonists,Platelet Antiaggregant,Platelet Antiaggregants,Platelet Inhibitor,Protease-Activated Receptor-1 Antagonists,Antiplatelet Drugs,Blood Platelet Aggregation Inhibitors,Blood Platelet Antagonists,Blood Platelet Antiaggregants,Platelet Inhibitors,Agent, Antiplatelet,Aggregation Inhibitor, Platelet,Antagonist, Blood Platelet,Antagonist, Platelet,Antiaggregant, Blood Platelet,Antiaggregant, Platelet,Drug, Antiplatelet,Inhibitor, Platelet,Inhibitor, Platelet Aggregation,PAR 1 Antagonists,Platelet Antagonist, Blood,Platelet Antiaggregant, Blood,Protease Activated Receptor 1 Antagonists
D005260 Female Females
D006083 Graft Occlusion, Vascular Obstruction of flow in biological or prosthetic vascular grafts. Graft Restenosis, Vascular,Vascular Graft Occlusion,Vascular Graft Restenosis,Graft Restenoses, Vascular,Occlusion, Vascular Graft,Restenosis, Vascular Graft
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006471 Gastrointestinal Hemorrhage Bleeding in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM. Hematochezia,Hemorrhage, Gastrointestinal,Gastrointestinal Hemorrhages,Hematochezias
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068342 Aspirin, Dipyridamole Drug Combination A drug combination of aspirin and dipyridamole that functions as a PLATELET AGGREGATION INHIBITOR, used to prevent THROMBOSIS and STROKE in TRANSIENT ISCHEMIC ATTACK patients. Aggrenox,Asasantin,Asasantin Retard,Aspirin-Dipyridamole Drug Combination,Extended-Release Dipyridamole-Aspirin,TX 3301,TX-3301,3301, TX,Aspirin Dipyridamole Drug Combination,Combination, Aspirin-Dipyridamole Drug,Dipyridamole-Aspirin, Extended-Release,Drug Combination, Aspirin-Dipyridamole,Extended Release Dipyridamole Aspirin,Retard, Asasantin

Related Publications

P Y Fan, and C C Lee, and S H Liu, and I-J Li, and C H Weng, and K H Tu, and M Y Hsieh, and C F Kuo, and T-Y Chang, and Y C Tian, and C W Yang, and H H Wu
July 1969, Radiology,
P Y Fan, and C C Lee, and S H Liu, and I-J Li, and C H Weng, and K H Tu, and M Y Hsieh, and C F Kuo, and T-Y Chang, and Y C Tian, and C W Yang, and H H Wu
January 2019, PeerJ,
P Y Fan, and C C Lee, and S H Liu, and I-J Li, and C H Weng, and K H Tu, and M Y Hsieh, and C F Kuo, and T-Y Chang, and Y C Tian, and C W Yang, and H H Wu
January 2024, Current vascular pharmacology,
P Y Fan, and C C Lee, and S H Liu, and I-J Li, and C H Weng, and K H Tu, and M Y Hsieh, and C F Kuo, and T-Y Chang, and Y C Tian, and C W Yang, and H H Wu
June 2018, World journal of surgery,
P Y Fan, and C C Lee, and S H Liu, and I-J Li, and C H Weng, and K H Tu, and M Y Hsieh, and C F Kuo, and T-Y Chang, and Y C Tian, and C W Yang, and H H Wu
March 1969, Southern medical journal,
P Y Fan, and C C Lee, and S H Liu, and I-J Li, and C H Weng, and K H Tu, and M Y Hsieh, and C F Kuo, and T-Y Chang, and Y C Tian, and C W Yang, and H H Wu
June 1967, The Journal of urology,
P Y Fan, and C C Lee, and S H Liu, and I-J Li, and C H Weng, and K H Tu, and M Y Hsieh, and C F Kuo, and T-Y Chang, and Y C Tian, and C W Yang, and H H Wu
February 1974, Orvosi hetilap,
P Y Fan, and C C Lee, and S H Liu, and I-J Li, and C H Weng, and K H Tu, and M Y Hsieh, and C F Kuo, and T-Y Chang, and Y C Tian, and C W Yang, and H H Wu
March 2023, The journal of vascular access,
P Y Fan, and C C Lee, and S H Liu, and I-J Li, and C H Weng, and K H Tu, and M Y Hsieh, and C F Kuo, and T-Y Chang, and Y C Tian, and C W Yang, and H H Wu
August 2018, BMC nephrology,
P Y Fan, and C C Lee, and S H Liu, and I-J Li, and C H Weng, and K H Tu, and M Y Hsieh, and C F Kuo, and T-Y Chang, and Y C Tian, and C W Yang, and H H Wu
June 2022, International journal of environmental research and public health,
Copied contents to your clipboard!